Q3 2021 13F Holders as of 30 Sep 2021
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
71,366,920
-
Number of holders
-
110
-
Total 13F shares, excl. options
-
34,491,766
-
Shares change
-
+2,258,477
-
Total reported value, excl. options
-
$1,542,710,693
-
Value change
-
+$110,759,163
-
Number of buys
-
69
-
Number of sells
-
-32
-
Price
-
$44.68
Significant Holders of C4 Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CCCC) as of Q3 2021
125 filings reported holding CCCC - C4 Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q3 2021.
C4 Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CCCC) has 110 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 34,491,766 shares
of 71,366,920 outstanding shares and own 48.33% of the company stock.
Largest 10 shareholders include PRICE T ROWE ASSOCIATES INC /MD/ (3,957,743 shares), BlackRock Inc. (3,157,207 shares), RTW INVESTMENTS, LP (2,494,965 shares), PERCEPTIVE ADVISORS LLC (2,258,566 shares), VANGUARD GROUP INC (1,938,575 shares), STATE STREET CORP (1,658,630 shares), Bain Capital Life Sciences Investors, LLC (1,642,209 shares), ArrowMark Colorado Holdings LLC (1,514,620 shares), RA CAPITAL MANAGEMENT, L.P. (1,377,569 shares), and WASATCH ADVISORS INC (1,342,047 shares).
This table shows the top 110 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.